Zoetis Inc. (NYSE:ZTS) Holdings Raised by Calamos Advisors LLC

Calamos Advisors LLC boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 15.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 210,885 shares of the company's stock after buying an additional 27,579 shares during the quarter. Calamos Advisors LLC's holdings in Zoetis were worth $34,359,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP raised its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company's stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Price Performance

Shares of Zoetis stock traded up $0.30 on Tuesday, hitting $172.24. The company had a trading volume of 2,696,175 shares, compared to its average volume of 2,685,644. The business has a 50-day simple moving average of $169.48 and a 200-day simple moving average of $179.39. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market cap of $77.71 billion, a PE ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts' expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $1.36 earnings per share. Research analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis's previous quarterly dividend of $0.43. Zoetis's dividend payout ratio is 37.59%.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective on the stock. Morgan Stanley dropped their price objective on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.